Summary Six different immunisation regimes have been used to generate spleen cells with reactivity against human pancreatic exocrine cancer. Immunised spleen cells were fused with an NSO/1 myeloma line and supernatants from these hybridomas selectively screened for monoclonal antibodies which bound predominantly to a pacreatic cancer cell line (GER) . The spleen cells from hairy litter mates immunised with pancreatic cancer xenograft homogenates and viable GER cells generated 13% of hybridoma supernatants which showed some selectivity for GER pancreatic cancer cells in a fixed cell ELISA assay. The other methods produced only 4% of hybrids with selectivity for GER cells. The antigen distribution on gluteraldehyde fixed cells was similar to that found for viable cell monolayers but many antigens were unstable on formalin fixation. Immunohistochemical staining of GER cells grown on glass slides showed a heterogeneity of antigen distribution with up to 70% of the cells exhibiting a vesicular pattern of staining. Fifty percent of the antibodies which bound to GER cells were also reactive against antigens in formalin-fixed paraffin-embedded tissue sections of the original GER tumour. Monoclonal antibody DD9E7 identified an antigen expressed on 12/14 pancreatic adenocarcinomas. The antibody showed strong staining of malignant luminal membrances and cytoplasm. The antigen was also present in normal salivary and sweat glands, and colon and breast carcinomas, but its tissue distribution was unlike that of CEA or EMA. The expression of this antigen in 12/14 of pancreatic carcinomas suggests that DD9E7 may be a useful reagent for pancreatic tumour detection.
As with many of the other common solid cancers, the availability of an antibody with 'useful selectivity' for pancreatic exocrine adenocarcinoma would contribute significantly to diagnostic and therapeutic possibilities. A monoclonal antibody Cal9-9, prepared against a colon carcinoma cell line, has been shown to bind to pancreatic cancer, as well as other gastroinstestinal cancer tissue sections (Atkinson et al., 1982) , but only two groups have focussed on the pancreas itself as the source of immunogen. Metzgar et al., (1982) have produced a number of monoclonals against ductular epithelium and tumour tissue using a pancreatic tumour cell line, and Parsa et al. (1982) have prepared a monoclonal against normal pancreatic duct cells and indentified the antigen on foetal and adult normal pancreas, as well as pancreatic tumours and cell lines.
A possible route to the production of selective antibodies was suggested by our earlier work (Grant & Duke, 1981; Davies et al., 1983; Mathews et al., 1984) . This showed that human cancer-cell components shed into the circulation of nude animals bearing human tumour xenografts will stimulate the production of antibodies when this serum is injected into immunocompetent hairy litter mates. When serum was taken from animals bearing pancreatic tumour xenografts, the antibodies produced in the hairy litter mates were predominantly selective for pancreatic cancer cells GER (Grant & Duke, 1981) . In the present study, we have looked at this and five other procedures for generating spleen cells with reactivity against pancreatic cancer. One of these regimes, combined with a selective screening assay for antibodies which bind predominantly to pancreatic cancer cells, has enabled us to generate a number of potentially useful monoclonals.
Materials and methods

Cell lines
Human pancreatic exocrine adenocarinoma cell lines GER (Grant et al., 1979) and WAD (Davies et al., 1983) ; colon carcinoma cell lines AC and EC (Walton et al., 1985) , and HT29 (Fogh & Trempe, 1975) ; renal carcinoma GYL (Matthews et al., 1982) (Young et al., 1973) and a fibrosarcoma HT1080 (Rasheed et al., 1974) Mouse antiserum against pooled, normal lymphocytes (MHL) was prepared as previously described (Grant & Duke, 1981) .
Fusion
Cell fusion was carried out essentially according to published methods (Kohler & Milstein, 1975; Galfre et al., 1977) . Hybrids were diluted in HAT medium (Gibco) +15% FCS to lx 105 cellsml-I and plated out in 96 well (Costar) plates. Hybrids which produced antibody were cloned by limiting dilution into 96 well plates or single clones were removed with a micropipette into 24 well plates containing a feeder layer of mouse spleen cells (1 x 104 per well). Hybrids were stored in liquid nitrogen in 90% FCS 10% DMSO. Large quantities of immunoglobulin (Ig) were prepared by injecting 1 x 107 hybridoma cells i.p. into nude beige mice (nu/nu-bg/bg). Ascitic fluid was collected after 10-14 days and IgG separated by affinity chromatography on protein-A Sepharose (Pharmacia).
Screening of hybridoma supernatants Hybridoma supernatants (10-20 days after fusion) were tested for Ig production against tumour cells using sheep anti-mouse Ig urease conjugated antibody (SAMIg) in a modified ELISA assay (Sera Labs). Tumour cells (5 x 104 per well) or lymphocytes (105 per well) were added to poly-L-lysine treated 96 well PVC plates (Titertek-Flow) and fixed with 0.05% glutaraldehyde (Suter et al., 1980; Cobbold & Waldmann, 1981) , or 10% formaldehyde in PBS. (The plates could be stored in PBS containing 1% FCS, 0.25% BSA, 0.05% Tween 20 and 0.02% sodium azide for one month at 4°C). Viable cells were grown on y-irradiated PVC plates (Titertek) for 24-48 h to obtain a confluent monolayer, washed and used immediately. Following 30-60min incubation with 50pl hybridoma supernatant at room temperature, cells were washed with 0.05% Tween 20 in PBS and incubated with 50jl SAMlg (1:250 dilution) for 1 hr 37°C. After extensive washing in PBS and H20, the colour was developed with 50 pd urease substrate. The reaction was stopped by the addition of 20 jl 1% w/v thiomersal and plates read at 588 nM on a Titertek Multiscan. Mouse antiserum against pooled normal human lymphocytes (MHL) and HAT medium were used as positive and negative controls respectively. Hybridoma supernatants were screened initially for antibody binding to glutaraldehyde fixed pancreatic carcinoma cells GER. Positive wells (the colour change was associated with an OD of >0.07) were rescreened against glutaraldehyde fixed HT29, GYL and HL. Only wells which were predominantly reactive against GER were cloned. Ig subclass was determined by ELISA assay using 1/100 dilution goat anti-mouse IgGl, IgG2a, IgG2b, IgA and IgM (Nordic Immunological Labs).
Immunocytochemical localisation Hybridoma supernatants were tested on formalin fixed paraffin embedded tissue sections using the indirect immunoperoxidase technique and an affinity-purified goat anti-mouse conjugate (Amersham International, UK). Endogenous peroxidase was inhibited by a sequence of 6.0% hydrogen peroxide, 2.5% periodic acid and 0.02% potassium borohydride (Heyderman, 1979) . Supernatants of interest were screened on a wide range of normal and malignant tissue sections, and compared with the pattern of staining found with monoclonal antibodies against CEA (Amersham International), epithelial membrane antigen EMA and a monoclonal antibody against the shared CEA/NCA determinant (Mab 122, Dr Mach, Lausanne).
Results
Comparison of immunisation regimes Thirty successful fusions were carried out using 6 different immunisation regimes. As can be seen in Table I , in all but one of the immunisation methods (HLM immunised with tbnm serum), over 70% of the wells produced hybrid clones. In general, 1-3 discreet clones were produced in each well. These could be individually removed with a micropipette and grown up for further cloning by limiting dilution. This method proved to be more successful than cloning by limiting dilution in the first instance.
The largest percentage of hybrid containing wells producing antibody (32%) which bound to glutaraldehyde fixed target cells (Table 1 , column 2) was found when spleen cells from hairy litter mates, immunised with homogenates of human pancreatic xenografts, were fused with NSO/1 cells (method 2b). This method of immunisation also generated many more hybridoma supernatants which were shown to be predominantly reactive against GER pancreatic carcinoma cells on a second screening (13%). Spleens taken from chimaeric animals 2, 6, and 7 days after i.v. injection of HLM spleen cells did not produce successful fusions, even though luminal membranes and cytoplasm (Figure 1 ), while included pancreatic islets were negative and acini and non-neoplastic ducts were often only weakly stained (Figure 2) . In colorectal carcinomas, staining was mainly seen in the necrotic debris within acini while many luminal membranes were negative or only weakly stained (Figure 3 ). This was unlike the luminal pattern of staining found with a monoclonal against CEA (Figure 4) . In 3/7 ductal carcinomas of the breast there was a grandular distribution of reaction product in the cytoplasm of a small population of tumour cells, quite unlike the luminal pattern of staining found with anti-EMA. DD9E7 also stained the supranuclear cytoplasm in some ducts and acini of normal human submandibular salivary gland and showed a luminal pattern of staining in normal colon and eccrine sweat glands. Except for included polymorphs and macrophages, which were stained in all sections, pituitary and placenta were negative, as were normal thyroid and a renal cell carcinoma. The immuno-cytochemical screening was also extended to cell lines which had been grown on glass slides prior to formalin fixation. The pancreatic cell line (GER), which was used as the immunogen, showed a heterogeneity of distribution with up to 70% of the cells showing a distinctive vesicular pattern of staining ( Figure 5 ). In contrast, a fibrosarcoma HT1080 was completely negative ( Figure 6 ). Using the other methods only 4% of the hybrids produced antibody with selectivity for GER cells. Spleens from nude mice bearing tumour xenografts produced hybrids, despite their incomplete T cell system, but very few antibodies showed any selectivity. These results are similar to those obtained using tumour bearing immune-suppressed mice (Herlyn et al., 1983) . Spleens from hairy litter mates immunised with serum from GER tumour bearing mice were successful at producing antibody secreting hybrids, but again, the antibodies were relatively unselective. The use of a modified ELISA assay made it possible to identify rapidly hybrid wells of potential usefulness for cloning and subsequent immunohistochemical localisation studies. Glutaraldehyde fixation of the target cells was preferred to formaldehyde since many antigens were unstable on formalin fixation. The reactions found on glutaraldehyde fixation were also very similar to those present on viable cell monolayers and may more realistically reflect the antigen distribution in vivo. However, the ELISA assay was limited to the initial screening, since it could not allow for either the heterogeneity of the cell population or distribution of antigen on the cell surface. Immunohistochemical staining of GER cells showed that -70% of the cells exhibited antigen when the cells were approaching confluency in normal culture conditions, and the antigen had a vesicular pattern of distribution.
Fifty per cent of the antibodies which bound to GER cells were also reactive against antigens retained on formalin-fixed paraffin embedded tissue sections. This paralleled the loss of antigen activity found on formalin fixation of target cells in the ELISA assay. The most intensely staining monoclonal antibody, DD9E7, identified an antigen which was present in large amounts in 12/14 of pancreatic adenocarcinomas, absent from islets and variably expressed on normal acini ducts and ductules. The antigen was also found in colon and breast carcinomas and a number of normal tissues but its immunohistochemical pattern was different to that found with antibodies against CEA or EMA (Heyderman et al., 1979; Grahame et al., 1985) . Consistent staining of polymorphs and macrophages in all sections suggested the antigen may be an NCA-like material (Mach & Putztnaseri, 1972; Von Kleist et al., 1972) . The tissue distribution of the antigen together with preliminary studies, which show that DD9E7 binds to a component of -55,00 mol. w in GER cell lysates (Winterbourne & Grant; unpublished observations) , suggest that the antigen recognised by DD9E7 is unlike the sialoganglioside and mucin-like antigens recognised by CA19-9 (Magnani et al., 1982; and Du-Pan-2 (Borowitz et al., 1984) . Figure 4 Another area of the same tumour as in colon stained with DD9E7. The staining is mainly in Figure 3 stained with a monoclonal antibody to CEA.
the necrotic debris, reactive polymorphs and macroThe staining is mainly on the luminal membrane of phages in the stroma (x 125). malignant acini, and in the necrotic debris (x 125). This study has shown that tumour cells growing in vivo as xenografts in nude mice are an ideal immunogen, when injected into syngenic relatives (nu/ +), for the production of monoclonal antibodies to pancreatic tumour cells GER. One of these monoclonal antibodies, DD9E7, binds to an antigen present in pancreatic carcinomas. Its detection by DD9E7 may prove useful for both w i~~~~~~~~~~~~~~ Figure 6 Fibrosarcoma cell line HT1080 also grown on slide and stained with DD9. No staining is seen ( x 500).
immunohistochemical and tumour localisation studies, and we are currently isolating the antigen for further biochemical analysis.
